The role of rosuvastatin in the contemporary cardiologic pharmacotherapy Review article
Article Sidebar
Published:
Sep 30, 2010
Keywords:
rosuvastatin, JUPITER study, hsCRP, dyslipidemia
Main Article Content
Abstract
Statins are nowadays one of the most common used drug groups. Studies performed during last few decades showed, that statins should be prescribed in many clinical conditions, not only those concerned with cardiology. HMG-CoA reductase inhibitors are consider to be a key point in pharmacological secondary prevention of cardiovascular events. In practice however in many patients there are still problems with reaching cholesterol goals, so that new methods of mono- and polytherapy are needed. Rosuvastatin, the strongest representative of the group, now available on polish market, have been put at the center of attention due to the recent JUPITER study results. It has been shown, that in generally healthy patients without cardiovascular diseases, with normal LDL cholesterol concentration but increased hsCRP level rosuvastatin can significantly reduce global cardiovascular risk. In this article, as a background for the discussion about rosuvastatin in the most important trials, authors describe present role of the statins in guidelines referring to cardiovascular diseases.
Article Details
How to Cite
Wełnicki , M., Folga, A., & Mamcarz , A. (2010). The role of rosuvastatin in the contemporary cardiologic pharmacotherapy. Medycyna Faktow (J EBM), 3(3(8), 35-42. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2575
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Banach M., Rysz J.: Algorytm postępowania w chorobach sercowo-naczyniowych z zastosowaniem statyn. Przewodnik Lekarza. Zeszyt specjalny – statyny: A46.
2. Folga A., Chmielewski M., Mamcarz A.: Statyny. Co należy wiedzieć o…? Biblioteka Kardioprofilu. Medical Education, Warszawa 2010.
3. Gąsior M., Czekaj A.D., Przybylska K., Janecka A.M., Siedlecki Ł.: Plejotropowe działanie statyn. Choroby Serca i Naczyń 2008; 5(3): 141-145.
4. Podstawy EBM. Gajewski P., Jaeschk R., Brożek J. (red.). Medycyna Praktyczna, Kraków 2008.
5. Guidelines on the management of stable angina pectoris: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. European Heart Journal [online: doi:10.1093/eurheartj/ehl002].
6. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. European Heart Journal 2008; 29: 2909-2945 [online: doi:10.1093/eurheartj/ehn416].
7. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. European Heart Journal 2007; 28: 1598-1660 [online: doi:10.1093/eurheartj/ehm161].
8. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2010. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabetologia Praktyczna 2010; 11(supl. A).
9. Postępowanie w udarze niedokrwiennym mózgu i przemijającym napadzie niedokrwienia mózgu. Wytyczne European Stroke Organization 2008. Medycyna Praktyczna. Wydanie specjalne 2009; 1 (na podstawie: Cerebrovascular Diseases 2008; 25: 457-507).
10. Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (ACC/AHA/ESC 2006 Guidelines for Management of Patients With). Europace 2006; 8: 746-837.
11. Acute and Chronic Heart Failure (Diagnosis and Treatment). ESC Clinical Practice Guidelines. Eur. Heart J. 2008; 29: 2388-2442.
12. Zalecenia ESH/ESC dotyczące leczenia nadciśnienia tętniczego – 2007 rok. 2007 Guidelines for the Management of Arterial Hypertension. Nadciśnienie Tętnicze 2007; Suplement D.
13. Wełnicki M., Mamcarz A.: Zwiększenie skuteczności terapii hipolipemizującej – komentarz do badania IN-CROSS. Medycyna Faktów 2010; 3/1(6): 30-32.
14. Wełnicki M., Mamcarz A.: Komentarz do artykułu W.H. Smileya Postępowanie w przypadku nietolerancji statyn. Medycyna po Dyplomie 2010 maj; 19, 5(170): 86-87.
15. Farnier M., Averna M., Missault L., Vaverkova H., Viigimaa M., Massaad R., Vandormael K., Johnson-Levonas A.O., Brudi P.: Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy – The IN-CROSS study. Int. J. Clin. Pract. 2009; 63(4): 547-559 [online: doi: 10.1111/j.1742-1241.2009.02022.x].
16. The ACCORD investigators. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 2010 [online: doi: 10.1056/NEJMoa1001282, http://www.nejm.org].
17. Ridker P.M. and on behalf of the JUPITER Study Group: Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein: Rationale and Design of the JUPITER Trial. Circulation 2003; 108: 2292-2297.
18. Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-1718.
19. Ridker P.M., Danielson E., Fonseca F.A.H., Genest J., Gotto A.M. Jr., Kastelein J.J.P., Koenig W., Libby P., Lorenzatti A.J., MacFadyen J.G., Nordestgaard B.G., Shepherd J., Willerson J.T., Glynn R.J.; for the JUPITER Study Group: Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N. Engl. J. Med. 2008; 359: 2195-207.
20. Ridker P.M., MacFadyen J., Cressman M., Glynn R.J.: Efficacy of Rosuvastatin Among Men and Women With Moderate Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein A Secondary Analysis From the JUPITER (Justification for the Use of Statins in Prevention – an Intervention Trial Evaluating Rosuvastatin) Trial. JACC 2010 March 23; 55(12): 1266-73.
21. Glynn R.J., Danielson E., Fonseca F.A.H., Genest J., Gotto A.M. Jr., Kastelein J.J.P., Koenig W., Libby P., Lorenzatti A.J., MacFadyen J.G., Nordestgaard B.G., Shepherd J., Willerson J.T., Ridker P.M.: A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism. N. Engl. J. Med. 2009; 360: 1851-1861.
22. Betteridge D.J., Gibson J.M., on behalf of the ANDROMEDA Study Investigators: Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. Diabet. Med. 2007; 24: 541-549.
23. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study Christian Berne, Annica Siewert-Delle and the URANUS study investigators. Cardiovascular Diabetology 2005; 4: 7 [online: doi: 10.1186/1475-2840-4-7].
24. Sorof J., Berne Ch., Siewert-Delle A., J0rgensen L., Sager P. on behalf of the URANUS study investigators: Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients. Diabetes Research and Clinical Practice 2006; 72: 81-87.
25. Faergeman O., Hill L., Windler E., Wiklund O., Asmar R., Duffield E., Sosef F. on behalf of the ECLIPSE study investigators: Efficacy and Tolerability of Rosuvastatin and Atorvastatin when Force-Titrated in Patients with Primary Hypercholesterolemia Results from the ECLIPSE Study. Cardiology 2008; 111: 219-228.
26. Ballantyne C.M., Bertolami M., Hernandez Garcia H.R., Nul D., Stein E.A., Theroux P., Weiss R., Cain V.A., Raichlen J.S.: Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am. Heart J. 2006; 151: 975.e12975.e9.
27. Jones P.H., Davidson M.H., Stein E.A., Bays H.E., McKenney J.M., Miller E., Cain V.A., Blasetto J.W. for the STELLAR Study Group: Comparison of the Efficacy and Safety of Rosuvastatin Versus Atorvastatin, Simvastatin, and Pravastatin Across Doses (STELLAR Trial). Am. J. Cardiol. 2003; 92: 152-160.
28. Crouse J.R. III, Raichlen J.S., Riley W.A., Evans G.W., Palmer M.K., O’Leary D.H., Grobbee D.E., Bots M.L. for the METEOR Study Group: Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals With Subclinical Atherosclerosis The METEOR Trial. JAMA 2007; 297: 1344-1353.
29. Nissen S.E., Nicholls S.J., Sipahi I. et al. for the ASTEROID Investigators: Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis The ASTEROID Trial. JAMA 2006; 295: 1556-1565.
30. Kjekshus J., Apetrei E., Barrios V., Böhm M. et al.: Rosuvastatin in Older Patients with Systolic Heart Failure. The New England Journal of Medicine 2007 Nov 29; 35(22): 2248.
2. Folga A., Chmielewski M., Mamcarz A.: Statyny. Co należy wiedzieć o…? Biblioteka Kardioprofilu. Medical Education, Warszawa 2010.
3. Gąsior M., Czekaj A.D., Przybylska K., Janecka A.M., Siedlecki Ł.: Plejotropowe działanie statyn. Choroby Serca i Naczyń 2008; 5(3): 141-145.
4. Podstawy EBM. Gajewski P., Jaeschk R., Brożek J. (red.). Medycyna Praktyczna, Kraków 2008.
5. Guidelines on the management of stable angina pectoris: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. European Heart Journal [online: doi:10.1093/eurheartj/ehl002].
6. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. European Heart Journal 2008; 29: 2909-2945 [online: doi:10.1093/eurheartj/ehn416].
7. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. European Heart Journal 2007; 28: 1598-1660 [online: doi:10.1093/eurheartj/ehm161].
8. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2010. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabetologia Praktyczna 2010; 11(supl. A).
9. Postępowanie w udarze niedokrwiennym mózgu i przemijającym napadzie niedokrwienia mózgu. Wytyczne European Stroke Organization 2008. Medycyna Praktyczna. Wydanie specjalne 2009; 1 (na podstawie: Cerebrovascular Diseases 2008; 25: 457-507).
10. Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (ACC/AHA/ESC 2006 Guidelines for Management of Patients With). Europace 2006; 8: 746-837.
11. Acute and Chronic Heart Failure (Diagnosis and Treatment). ESC Clinical Practice Guidelines. Eur. Heart J. 2008; 29: 2388-2442.
12. Zalecenia ESH/ESC dotyczące leczenia nadciśnienia tętniczego – 2007 rok. 2007 Guidelines for the Management of Arterial Hypertension. Nadciśnienie Tętnicze 2007; Suplement D.
13. Wełnicki M., Mamcarz A.: Zwiększenie skuteczności terapii hipolipemizującej – komentarz do badania IN-CROSS. Medycyna Faktów 2010; 3/1(6): 30-32.
14. Wełnicki M., Mamcarz A.: Komentarz do artykułu W.H. Smileya Postępowanie w przypadku nietolerancji statyn. Medycyna po Dyplomie 2010 maj; 19, 5(170): 86-87.
15. Farnier M., Averna M., Missault L., Vaverkova H., Viigimaa M., Massaad R., Vandormael K., Johnson-Levonas A.O., Brudi P.: Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy – The IN-CROSS study. Int. J. Clin. Pract. 2009; 63(4): 547-559 [online: doi: 10.1111/j.1742-1241.2009.02022.x].
16. The ACCORD investigators. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 2010 [online: doi: 10.1056/NEJMoa1001282, http://www.nejm.org].
17. Ridker P.M. and on behalf of the JUPITER Study Group: Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein: Rationale and Design of the JUPITER Trial. Circulation 2003; 108: 2292-2297.
18. Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-1718.
19. Ridker P.M., Danielson E., Fonseca F.A.H., Genest J., Gotto A.M. Jr., Kastelein J.J.P., Koenig W., Libby P., Lorenzatti A.J., MacFadyen J.G., Nordestgaard B.G., Shepherd J., Willerson J.T., Glynn R.J.; for the JUPITER Study Group: Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N. Engl. J. Med. 2008; 359: 2195-207.
20. Ridker P.M., MacFadyen J., Cressman M., Glynn R.J.: Efficacy of Rosuvastatin Among Men and Women With Moderate Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein A Secondary Analysis From the JUPITER (Justification for the Use of Statins in Prevention – an Intervention Trial Evaluating Rosuvastatin) Trial. JACC 2010 March 23; 55(12): 1266-73.
21. Glynn R.J., Danielson E., Fonseca F.A.H., Genest J., Gotto A.M. Jr., Kastelein J.J.P., Koenig W., Libby P., Lorenzatti A.J., MacFadyen J.G., Nordestgaard B.G., Shepherd J., Willerson J.T., Ridker P.M.: A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism. N. Engl. J. Med. 2009; 360: 1851-1861.
22. Betteridge D.J., Gibson J.M., on behalf of the ANDROMEDA Study Investigators: Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. Diabet. Med. 2007; 24: 541-549.
23. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study Christian Berne, Annica Siewert-Delle and the URANUS study investigators. Cardiovascular Diabetology 2005; 4: 7 [online: doi: 10.1186/1475-2840-4-7].
24. Sorof J., Berne Ch., Siewert-Delle A., J0rgensen L., Sager P. on behalf of the URANUS study investigators: Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients. Diabetes Research and Clinical Practice 2006; 72: 81-87.
25. Faergeman O., Hill L., Windler E., Wiklund O., Asmar R., Duffield E., Sosef F. on behalf of the ECLIPSE study investigators: Efficacy and Tolerability of Rosuvastatin and Atorvastatin when Force-Titrated in Patients with Primary Hypercholesterolemia Results from the ECLIPSE Study. Cardiology 2008; 111: 219-228.
26. Ballantyne C.M., Bertolami M., Hernandez Garcia H.R., Nul D., Stein E.A., Theroux P., Weiss R., Cain V.A., Raichlen J.S.: Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am. Heart J. 2006; 151: 975.e12975.e9.
27. Jones P.H., Davidson M.H., Stein E.A., Bays H.E., McKenney J.M., Miller E., Cain V.A., Blasetto J.W. for the STELLAR Study Group: Comparison of the Efficacy and Safety of Rosuvastatin Versus Atorvastatin, Simvastatin, and Pravastatin Across Doses (STELLAR Trial). Am. J. Cardiol. 2003; 92: 152-160.
28. Crouse J.R. III, Raichlen J.S., Riley W.A., Evans G.W., Palmer M.K., O’Leary D.H., Grobbee D.E., Bots M.L. for the METEOR Study Group: Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals With Subclinical Atherosclerosis The METEOR Trial. JAMA 2007; 297: 1344-1353.
29. Nissen S.E., Nicholls S.J., Sipahi I. et al. for the ASTEROID Investigators: Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis The ASTEROID Trial. JAMA 2006; 295: 1556-1565.
30. Kjekshus J., Apetrei E., Barrios V., Böhm M. et al.: Rosuvastatin in Older Patients with Systolic Heart Failure. The New England Journal of Medicine 2007 Nov 29; 35(22): 2248.